# Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

> **NCT01618370** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 705 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Radium-223 dichloride (BAY88-8223)

## Key facts

- **NCT ID:** NCT01618370
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-22
- **Primary completion:** 2014-08-13
- **Final completion:** 2016-02-28
- **Target enrollment:** 705 (ACTUAL)
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01618370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01618370, "Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01618370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*